Cargando…

Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis

Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and the predictors of these effects remain unclear. This meta-analysis provides a pooled estimate of the impact of statin use on HCC occurrence. Pooled effects were calculated using a random-effects model by means of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Facciorusso, Antonio, Abd El Aziz, Mohamed A, Singh, Siddharth, Pusceddu, Sara, Milione, Massimo, Giacomelli, Luca, Sacco, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225931/
https://www.ncbi.nlm.nih.gov/pubmed/32260179
http://dx.doi.org/10.3390/cancers12040874
_version_ 1783534168352751616
author Facciorusso, Antonio
Abd El Aziz, Mohamed A
Singh, Siddharth
Pusceddu, Sara
Milione, Massimo
Giacomelli, Luca
Sacco, Rodolfo
author_facet Facciorusso, Antonio
Abd El Aziz, Mohamed A
Singh, Siddharth
Pusceddu, Sara
Milione, Massimo
Giacomelli, Luca
Sacco, Rodolfo
author_sort Facciorusso, Antonio
collection PubMed
description Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and the predictors of these effects remain unclear. This meta-analysis provides a pooled estimate of the impact of statin use on HCC occurrence. Pooled effects were calculated using a random-effects model by means of the DerSimonian and Laird test. Primary endpoint was the time-dependent correlation between statin use and HCC incidence expressed as hazard ratio (HR), both crude and adjusted. The crude and adjusted odds ratios (OR) for HCC occurrence between statin users and non-users were analyzed. Twenty-five studies with 1,925,964 patients were included. Crude OR for HCC incidence was 0.59 (95% CI: 0.47–0.74), confirmed in adjusted analysis (OR: 0.74, 95% CI: 0.70–0.78). Adjusted HR was 0.73 (95% CI: 0.69–0.76). This effect was more pronounced in HBV patients (HR: 0.46, 95% CI: 0.36–0.60) and with a cumulative daily dose beyond 365 (HR: 0.27, 95% CI: 0.11–0.67). Lipophilic statins were associated with reduced HCC incidence (HR: 0.49, 95% CI: 0.39–0.62). Atorvastatin determined the greater magnitude of effect (HR: 0.43, 95% CI: 0.28–0.65). This meta-analysis demonstrates the beneficial chemopreventive effect of statins against HCC occurrence. This effect is dose-dependent and more pronounced with lipophilic statins.
format Online
Article
Text
id pubmed-7225931
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72259312020-05-18 Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis Facciorusso, Antonio Abd El Aziz, Mohamed A Singh, Siddharth Pusceddu, Sara Milione, Massimo Giacomelli, Luca Sacco, Rodolfo Cancers (Basel) Article Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and the predictors of these effects remain unclear. This meta-analysis provides a pooled estimate of the impact of statin use on HCC occurrence. Pooled effects were calculated using a random-effects model by means of the DerSimonian and Laird test. Primary endpoint was the time-dependent correlation between statin use and HCC incidence expressed as hazard ratio (HR), both crude and adjusted. The crude and adjusted odds ratios (OR) for HCC occurrence between statin users and non-users were analyzed. Twenty-five studies with 1,925,964 patients were included. Crude OR for HCC incidence was 0.59 (95% CI: 0.47–0.74), confirmed in adjusted analysis (OR: 0.74, 95% CI: 0.70–0.78). Adjusted HR was 0.73 (95% CI: 0.69–0.76). This effect was more pronounced in HBV patients (HR: 0.46, 95% CI: 0.36–0.60) and with a cumulative daily dose beyond 365 (HR: 0.27, 95% CI: 0.11–0.67). Lipophilic statins were associated with reduced HCC incidence (HR: 0.49, 95% CI: 0.39–0.62). Atorvastatin determined the greater magnitude of effect (HR: 0.43, 95% CI: 0.28–0.65). This meta-analysis demonstrates the beneficial chemopreventive effect of statins against HCC occurrence. This effect is dose-dependent and more pronounced with lipophilic statins. MDPI 2020-04-03 /pmc/articles/PMC7225931/ /pubmed/32260179 http://dx.doi.org/10.3390/cancers12040874 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Facciorusso, Antonio
Abd El Aziz, Mohamed A
Singh, Siddharth
Pusceddu, Sara
Milione, Massimo
Giacomelli, Luca
Sacco, Rodolfo
Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis
title Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis
title_full Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis
title_fullStr Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis
title_full_unstemmed Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis
title_short Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis
title_sort statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225931/
https://www.ncbi.nlm.nih.gov/pubmed/32260179
http://dx.doi.org/10.3390/cancers12040874
work_keys_str_mv AT facciorussoantonio statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis
AT abdelazizmohameda statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis
AT singhsiddharth statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis
AT pusceddusara statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis
AT milionemassimo statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis
AT giacomelliluca statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis
AT saccorodolfo statinusedecreasestheincidenceofhepatocellularcarcinomaanupdatedmetaanalysis